Granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) control the proliferation of human acute myeloid leukemia (AML) cells in vitro. Previously, we have shown that receptors for GM-CSF and IL-3 are often coexpressed on AML cells. Here we present experiments with purified AML blasts, normal monocytes, and granulocytes that were conducted t o analyze the properties of GM-CSF and IL-3 binding proteins in more detail. On AML cells from eight cases we demonstrate t w o types of GM-CSF receptors: one with low affinity (dissociation constant [kd] 5.1 t o 24.8 nmol/L) and one with a high affinity (kd 31 t o 104 pmol/L). These AML cells also expressed high affinity receptors for IL-3 (kd 24 t o 104 pmol/L). Cross-competition experiments showed that an excess concentration of nonlabeled IL-3 completely prevented the high affinity binding of radiolabled GM-CSF. This competition occurred at 37°C as well as 4°C. Low affinity GM-CSF binding was not affected by IL-3. Binding of RANULOCYTE MACROPHAGE colony-stimulat-G ing factor (GM-CSF) and interleukin-3 (IL-3) are hematopoietic growth factors (GF) with multilineage stimulative abilitie~'.~ that exert their effects on the cells through specific membrane re~eptors.~These factors also induce proliferation of acute myeloid leukemia (AML) GM-CSF and IL-3 receptors are frequently coexpressed on AML cells," and the mitogenic responses among the different cases of AML to GM-CSF and IL-3 often coincide." Parallel effects of GM-CSF and IL-3 on colony formation from purified normal human marrow progenitors have also been dem~nstrated.'~.'~ These studies suggest that the control of growth and differentiation of hematopoietic cells by IL-3 and GM-CSF is closely interrelated. Recently, evidence has been obtained for the existence of a receptor structure on AML blasts and leukemia cell lines with a high affinity for both GM-CSF and IL-3.I4-I6 In this study, we compare the abilities of AML cells, monocytes, and granulocytes to bind GM-CSF and IL-3. We confirm that AML blasts, as well as monocytes, express membrane structures and that can bind GM-CSF and IL-3 both with an equally high affinity (kd -60 pmol/L). Preliminary crosslinking experiments indicate that both GM-CSF and IL-3 bind to proteins with molecular weights (mol wts) of 130, 105, and 75 Kd, the latter probably being a product of proteolytic cleavage. In addition to this common GM-CSF/IL-3 binding site, three selective GM-CSF or IL-3 binding sites are distinguished: a low affinity GM-CSF receptor with no affinity for IL-3 (AML cells and monocytes), a high affinity IL-3 receptor that does not bind GM-CSF (monocytes and some cases of AML), and a receptor with intermediate affinity for GM-CSF that does not bind IL-3 (neutrophils).
Patients and purification of AML cells and normal cells.
Bone marrow (all cases except case no. 6) or peripheral blood (case no. 6) was taken from eight patients with AML diagnosed according to the French-American-British (FAB) classificati~n'~*'~ (AML case no. 8: FAB M1; case no. 2: FAB M2; case no. 6 FAB M3; case nos. 1, 3,4, radiolabeled IL-3 could be prevented by nonlabeled GM-CSF. In certain cases, this competition was complete. whereas in others only partial (49% t o 77%) reduction of the radiolabeled IL-3 binding was seen. On the basis of these ligand binding features, we propose the existence of three receptor types on AML cells: (1 ) low affinity GM-CSF receptors that do not bind IL-3, (2) dual high affinity GM-CSF/IL-3 receptors, and (3) high affinity IL-3 receptors that do not bind GM-CSF. We could also demonstrate these receptor types on normal monocytes. In addition, a fourth type of receptor was apparent on normal granulocytes (4). incapable of binding IL-3 and with an intermediate affinity for GM-CSF (-400 pmol/L). Chemical crosslinking showed that GM-CSF and IL-3 both bind t o proteins with molecular weight values of 130, 105, and 75, which provides additional evidence for the existence of a common GM-CSF/IL-3 receptor complex. 0 1990 by The American Society of Hematology. and 7: FAB M4; case no. 5: FAB M5). The leukemic cells were separated after bovine serum albumin density gradient (BSA) or Ficoll-Isopaque centrifugation and subsequent removal of E-rosetteforming cells" and cryopreserved. 6 The viability of the cells after thawing was always more than 95%. White blood cells (WBC) were separated from the blood of healthy subjects after sedimentation in 0.1% methylcellulose. Granulocytes were obtained as the sedimented cell fraction after Ficoll-Isopaque centrifugation of WBC and consisted of 90% to 95% neutrophils, 2% to 6% eosinophils, and 3% to 5% monocytes/lymphocytes. Monocytes were obtained from the Ficoll-Isopaque interface of WBC and subsequent removal of E-rosette-forming cells and consisted of 70% to 80% monocytes, 20% to 30% non-E-rosetting lymphocytes, and less than 2% granulocytes.
Recombinant human GM-CSF (CHO cell-derived; glycosilated, mol wt 20 to 30 Kd)20 was prepared and purified at Genetics Institute (Cambridge, MA). Recombinant human IL-3 (Yersinia-derived; nonglycosilated, mol wt 15 Kd) was prepared and purified at Gist Brocades (Delft, The Netherlands)." Both proteins were radiolabeled with Bolton and Hunter reagent (Amersham Laboratories, Amersham, UK)22 as described." Specific activity of radiolabeled GM-CSF and IL-3, as determined by self-displacement analysis;3 was 5 to 7 x 104cpm/ng for GM-CSF and 8 to 10 x 104cpm/ng for IL-3. The iodinated preparations retained their ability to stimulate colony formation by normal bone marrow cells in methylcellulose." Trichloracetic acid (TCA) precipitation showed less than 5% nonprecipitable radioactiv-ity for both factors. The maximum binding capacity was estimated at 40% to 65% for IL-3 and 50% to 95% for GM-CSF. In Scatchard calculations the "free" cpm were corrected for the maximum binding capacity.*'
Binding of labeled GM-CSF and IL-3 to AML blasts, monocytes, and granulocytes. GM-CSF and IL-3 binding to the cells was assessed as described." Equilibrium binding conditions for both GM-CSF and IL-3 at 37OC and O°C were reached in 1 and 17 hours, respectively.".'5.24 Two to seven times IO6 cells were incubated for 1 hour at 37OC or 18 hours at 4OC in 100 pL a Minimal Essential Medium with 1% BSA in the presence of 20 to 7,000 pmol/L radiolabeled IL-3 or GM-CSF with or without excess (ie, 200 nmol/L) nonlabeled factor. Specific binding was defined as the difference between the amount of radioactivity bound in the absence of nonlabeled factor, and the amount of radioactivity bound in the presence of excess nonlabeled factor. Experiments were conducted in duplicate. Receptor numbers and binding affinities were derived after Scatchard analysis and two affinity receptor analysis was performed by the R-Binding Binding characteristics of low affinity of GM-CSF binding sites were assessed by selfdisplacement of 1 nmol/L I2'I GM-CSF, essentially as has been described by Robb, Greene, and for the low affinity of IL-2 receptor.
Two to five times IO7 AML cells were incubated with radiolabeled IL-3 or GM-CSF (2 nmol/L) both with and without excess (200 nmol/L) nonlabeled IL-3 or GM-CSF. After 1 hour, the cells were chilled on ice and layered on top of 1 mL fetal calf serum (FCS). After centrifugation for 5 minutes, the cell pellet was rinsed twice in ice-cold Hanks' Balanced Salt Solution (HBSS) and resuspended in 300 pL phosphate-buffered saline (PBS). Ethylene glycolbisuccinimidyl succinate (EGS, Pierce Chemical Co, Rockford, IL) was then added at a final concentration of 1 mmol/L and incubated at 4OC for 30 minutes. After two acid washes with sodium citrate (pH 4) to remove noncrosslinked but receptorbound ligand," the cells were fragmented by repeatedly freezing and thawing in hypotonic phosphate-buffered solution (50 mmol/L sodium chloride, 2 mmol/L potassium chloride, and 5 mmol/L phosphate buffer). Membrane fragments were isolated after spinning down the nuclei by high speed centrifugation (90 minutes, 60,000 g ) . In all steps the protease inhibitors, phenyl methyl sulphonyl fluoride (PMSF; 2 mmol/L), leupeptin (10 pmol/L), iodoacetamide (2 mmol/L), pepstatin (10 pmol/L), and aprotinin 1
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k m mg/mL, were present. Pelleted membrane fragments were boiled in sodium dodecyl sulfate (SDS) buffer (0.2 mol/L Tris HCl, pH 6.8; 6% SDS; 5% 0-mercaptoethanol; 10% glycerol, and bromophenol blue) for 10 minutes and membrane preparations were then analyzed by SDS polyacrylamide gel electrophoresis (SDS-PAGE, 7.5%) under reducing conditions and subsequent autoradiography.
RESULTS
Binding of radiolabeled GM-CSF and IL-3 to leukemic cells. Binding of titrated concentrations of radiolabeled GM-CSF to AML cells (from 40 to 7000 pmol/L) consistently produced biphasic Scatchard plots indicating high and low affinity components (Fig 1A) . The average numbers of high affinity GM-CSF receptors among eight cases was estimated at 132 per cell (distribution 53 to 275 sites/cell; kd f SD: 59 + 22 pmol/L) ( Table 1) . Estimations of the numbers and affinity of the low affinity GM-CSF receptors derived from binding experiments with concentrations of radiolabeled GM-CSF up to 7,000 pmol/L showed considerable standard variations, since the estimation of the binding maximum in these calculations could only be reached by extrapolation. To assess the low affinity binding component more accurately, titrated concentrations of nonlabeled GM-CSF were added to the cells in the presence of 1 nmol/L radiolabeled *3M-CSF. From these experiments total binding of GM-CSF (labeled plus nonlabeled) to the cells could be calculated27 (Fig 1 B) . Subsequent calculations showed saturable binding at GM-CSF concentrations of 33 to 100 nmol/L with a kd of 5.1 to 24.6 nmol/L (mean + SD: 13.2 t 6.2 nmol/L). The average number of low affinity GM-CSF receptors was 4,688 per cell (range 1,099 to 11,900 sites/ cell). In all eight cases, receptors for IL-3 could be demonstrated on the AML cells ( Table 1 ). The average density of IL-3 binding sites was estimated at 117 per cell (range 14 to 234) and the average kd (+ SD) was estimated a t 57 f 26 pmol/L.
Competition of "'I GM-CSF binding to AML cells by ZL-3. Binding of radiolabeled GM-CSF to AML cells was For personal use only. on November 15, 2017. by guest www.bloodjournal.org From 2) ; kd values (pmol/L) are indicated in brackets. Low affinity GM-CSF binding was not competed for by nonlabeled IL-3 (see Fig 2) .
*Indicates specific binding detectable but too low for complete Scatchard analysis.
reduced by an excess concentration of nonlabeled IL-3 ( Fig   2A) . The difference between '251 GM-CSF binding in the absence and presence of nonlabeled IL-3 appeared as a readily saturable component of total binding (Fig 2B) . The Scatchard plot of these data shows that in the presence of IL-3 the steep segment of the biphasic curve disappeared, indicating that IL-3 prevented high affinity I2'I GM-CSF binding, but not low affinity I2'I GM-CSF binding (Fig 2C) . Data from eight cases of AML are summarized in Table 1 Table 1 ). In the remaining three cases this inhibition was partial (Fig 3B, Table 1 ). Scatchard analysis of the IL-3 receptors of the latter three cases showed that only 23% to 51% of the initially established numbers of receptors had remained detectable in the presence of excess GM-CSF (Table 1 ). The affinity of the latter receptors was comparable with the affinity of those that had been estimated in the absence of GM-CSF (Table 1 ). These results suggest that there are two different high affinity IL-3 binding sites in AML. The first one appears as a dual-binding site that can interact with GM-CSF and IL-3, and is detectable in all eight cases of AML. The second type of IL-3 binding site demonstrated in 3 of the 8 cases does not bind GM-CSF.
Cross-competition of 12'1 GM-CSF and I2'I IL-3 ut 4" C. Cross-competition of '"I IL-3 binding by GM-CSF and, reciprocally, "'1 GM-CSF binding by IL-3 was apparent within 1 hour of incubation at 37°C and 18 hours at 4°C (Fig  4) . The amount of acid-resistant radioactivity after 18 hours incubation at 4OC was approximately 8%, indicating that 92% of the radioactive ligand had remained surface-bound under these conditions (results not shown). These data suggest that the cross-inhibition of binding for both factors does not require active cell metabolism and therefore resulted from direct interference at the receptor level (rather than down-modulation).
Dose dependence of GM-CSF and IL-3 cross-inhibition. We then determined the comparative efficiency of GM-CSF and IL-3 as competitors for radiolabeled GM-CSF binding to AML cells, first of patient no. 5 (Fig SA) . For Displacement of radiolabeled GM-CSF by IL-3 was dosedependent, but leveled off at a higher plateau than GM-CSF in accordance with the fact that IL-3 competes for the high affinity GM-CSF binding sites only. From this experiment it was also evident that 200 nmol/L IL-3 (as used in the cross-competition experiments) was sufficient to occupy all high affinity dual GM-CSF/IL-3 binding sites. Displacement of radiolabeled IL-3 from AML cells of patient no. 7 by GM-CSF did not equal the displacement by IL-3 (Fig 5B) , illustrating that on these cells the two types of IL-3 receptors GM-CSF. The same experiment was performed with AML cells from another patient (case no. 4) showing complete inhibition of '*'I IL-3 binding by excess GM-CSF ( Fig 5C) . As expected, binding of radiolabeled IL-3 was displaced to the same extent by both IL-3 and GM-CSF, confirming that the cells from this AML case indeed carried the dual GM-CSF/IL-3 binding sites, but not the unique IL-3 binding site (Table 1) . From the observation that the displacement curves attained by nonlabeled GM-CSF and IL-3 are identical in this experiment, it appears that the common GM-CSF/IL-3 binding structure has equal affinity for both were present; ie, one competed and one not competed for by ligands (Fig 5C) . 
Binding of radiolabeled GM-CSF to normal cells.
Binding of radiolabeled GM-CSF to monocytes did not appear saturable at GM-CSF concentrations up to 5 nmol/L and the Scatchard plot was curvilinear (not shown), indicating that, similar to AML, high and low affinity GM-CSF binding was involved. Cross-competition with IL-3 showed that the high affinity component of '*'I GM-CSF binding could be inhibited by IL-3. Calculations from three experiments showed an average number of 207 high affinity binding sites (range 56 to 348) (Table 1 ) and 4,320 low affinity sites (range 1,087 to 7,892) for GM-CSF on monocytes. Binding of radiolabeled GM-CSF to normal granulocytes was saturable at a GM-CSF concentration of approximately 2 nmol/L and was not affected by the addition of 200 nmol/L IL-3 (Table 2) . Thus, the GM-CSF receptor on normal granulocytes appears not capable of binding IL-3. Scatchard analysis of 1251 GM-CSF binding to granulocytes from four different donors showed an average of 2,292 binding sites per cell (range 1,949 to 2,729) of single affinity with a kd of 400 f 50 pmol/L, which is intermediate between the high and low affinity GM-CSF receptors in AML.
Monocytes expressed 115 to 143 high affinity IL-3 binding sites per cell (kd 2 SD: 61 2 30), which were also partially inhibited by Binding of radiolabeled IL-3 to normal cells. excess nonlabeled GM-CSF (Table 1) . Scatchard analysis showed 38 to 112 high affinity IL-3 receptors per cell (kd * SD: 147 79) on granulocyte samples from three different donors. These samples contained 90% to 95% neutrophils, 2% to 6% eosionophils, and 3% to 5% monocytes/lymphocytes. Because eosinophils have been reported to express up to 2,000 IL-3 binding sites per cell," it is most likely that the eosinophils in these cell samples had been responsible for IL-3 binding.
Chemical crosslinking was performed to estimate the mol wts of the GM-CSF and IL-3 binding proteins. Affinity crosslinking using radiolabeled IL-3, GM-CSF, and AML cells is shown in Fig 6. The autoradiograph demonstrates the migration of three conjugates with apparent mol wts of 100, 130, and 155 Kd for 1251 GM-CSF (Fig 6, lane 1) . Also, three different conjugates for 1251 IL-3 with mol wts of 90, 120, and 145 Kd appeared ( Fig  6, lane 5) . In six separate experiments using cells from different patients, the same three bands for GM-CSF as well as IL-3 were observed. In the presence of 100-fold overdose nonlabeled GM-CSF or IL-3 in the initial binding reaction, no bands appeared on the autoradiograph (Fig 6, lanes 2, 4,  and 6 ). Crosslinking of '''I GM-CSF was significantly, although not completely, reduced in the presence of excess nonlabeled IL-3 (Fig 6, lane 3) . After subtraction of the mol wts of the ligands (GM-CSF, 25 Kd; IL-3,15 Kd), GM-CSF and IL-3 binding membrane proteins are estimated to have equal mol wts of 75,105, and 130 Kd.
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Dl SCU SSlON
In this study we provide evidence for the presence of a binding structure on AML cells and monocytes with high affinity for both IL-3 and GM-CSF. This conclusion has been based on two sets of experimental findings: (1) Radiolabeled ligand binding showed bidirectional cross-competition between GM-CSF and IL-3 binding to AML cells and monocytes. This competition occurred equally well at 37OC and 4OC. indicating that receptor down-modulation was not involved in the observed GM-CSF/IL-3 receptor interaction.
(2) Chemical crosslinking of GM-CSF and IL-3 to AML cells showed that both factors bind to proteins with similar electrophoretic mobility on SDS polyacrylamide gels with mol wts estimated at 70, 105, and 130 Kd. These findings are in agreement with observations recently made by other who postulated three subtypes of IL-3 and GM-CSF receptors on human leukemia cell lines and AML cells, one being capable of binding both ligands. We have at present no experimental data that could explain the mechanism of IL-3 and GM-CSF cross-competition. The fact that no sequence homology between GM-CSF and IL-3 has been found" would be remarkable although not impossible in view of a shared single binding domain on the receptor. Alternatively, the common GM-CSF/IL-3 binding structure may consist of two separate binding domains that each have high affinity for their respective ligands. Cross-competition between the two ligands could then occur through conformational changes on binding of either ligand preventing binding of the other. It is also possible that the binding domains are located in such proximity that binding of one ligand will preclude binding of the other due to steric hindrance.
We have obtained evidence for the presence of two types of GM-CSF receptors on AML cells and monocytes. In our experiments on human AML with concentrations of radiolabeled GM-CSF up to 6 to 7 nmol/L, Scatchard plots were in favor of two affinities. When comparable concentrations of radiolabeled GM-CSF were applied to granulocytes, complete saturation was evident (Table 2 and references 1 I, 24, 29, 30). indicating that the low affinity component that was observed in AML was not inherent to an artefact of the experimental procedure or the result of impaired binding of the ligand due to the labeling procedure. Further evidence for the existence of low affinity receptors for GM-CSF was derived from displacement of radiolabeled GM-CSF by its nonlabeled homolog (Figs 1 B and SA) and from crosslinking experiments with radiolabeled GM-CSF in the presence of IL-3 (Fig 6) . In earlier reports this distinction of two affinity GM-CSF receptor types has not been This discrepancy can be explained by the fact that the initial measurements were performed over only a limited range of free ligand concentrations. Consequently it becomes difficult to distinguish between single affinity versus multiple affinities because of failure to detect a curvature in the Scatchard plot, and one may inadvertently select the wrong model of data fitting. Indeed the existence of high and low affinity GM-CSF receptors is in agreement with later reports on human cell lines, monocytes, and AML cell^."^^^^'^ Crosslinking of GM-CSF binding membrane proteins showed three bands of which the lower was markedly broader than the upper two. The fact that omission of protease inhibitors produced an even broader lower band at the expense of the upper two (results not shown) suggested that this band is at least partially the product of proteolysis as has been demonstrated for the IL-3 receptor in mice. 34 Because the addition of excess IL-3 in the initial binding reaction with radiolabeled GM-CSF equally reduced the intensity of all three bands, these bands all appear related to the common GM-CSF/IL-3 binding structure (Fig 6, lane 3) . Crosslinking of IL-3 binding proteins showed components of equal mass.
Granulocytes express GM-CSF receptors that do not bind IL-3 and show an intermediate affinity as compared with the high and low affinity GM-CSF binding sites on AML cells and monocytes. The observation of intermediate affinity GM-CSF binding to granulocytes adds a third distinct GM-CSF receptor type. IL-3 competition experiments did not provide evidence for the presence of this receptor type on AML ( Table 2 ). The physiologic relevance of an intermediate affinity of GM-CSF receptor could be that neutrophils will be functionally activated by GM-CSF only at relatively high tissue concentrations of GM-CSF; eg, induced by bacterial infection.
The potential biologic role of low affinity GM-CSF binding to AML cells and monocytes remains elusive. Thus far no biologic effects have been reported in response to GM-CSF at the nmol concentration range. Possibly this low affinity GM-CSF binding site represents a precursor of the functional GM-CSF receptor.
The fact that 1L-3 and GM-CSF bind to common or closely related structures raises the possibility that alternative factors trigger the same target cells through a common receptor and perhaps activate the cells via identical intracellular signal pathways. This would explain the marked parallelism of stimulative abilities in normal precursor cells and AML of the two hematopoietins.
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